{"id":17396,"date":"2024-03-28T18:55:05","date_gmt":"2024-03-28T18:55:05","guid":{"rendered":"https:\/\/www.thermofisher.com\/blog\/analyteguru\/?p=17396"},"modified":"2024-05-07T16:07:06","modified_gmt":"2024-05-07T16:07:06","slug":"advanced-lc-ms-tools-and-software-solutions-to-ease-your-metabolite-identification-challenges","status":"publish","type":"post","link":"https:\/\/www.thermofisher.com\/blog\/analyteguru\/advanced-lc-ms-tools-and-software-solutions-to-ease-your-metabolite-identification-challenges\/","title":{"rendered":"Advanced LC-MS Tools and Software Solutions to Ease Your Metabolite Identification Challenges"},"content":{"rendered":"\n

This is the second of a three-part series on Thermo Fisher Scientific analytical instrument solutions for metabolite identification in the small molecule DMPK drug development process. If you missed part one, catch up here: Speed up the drug development process …<\/a><\/em><\/p>\n\n\n\n

Metabolite identification (MetID) using LC-MS instrumentation from in <\/em>vitro and in vivo <\/em>studies is a critical part of the drug development process, but having improper tools to assess drug metabolism can lead to serious and costly implications during clinical phases and \ua7f7 in the worst case \ua7f7 rejection of an NDI. Fortunately, Thermo Fisher Scientific offers advanced tools to avoid pitfalls related to improper MetID assessment.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Identifying metabolites in challenging matrices shouldn\u2019t be a challenge<\/strong><\/h3>\n\n\n\n

To determine the transformation site for metabolites typically requires fragmentation data, making it necessary to obtain fragmentation coverage of all metabolites. However, one of the main challenges in the profiling of drug metabolites is that complex background signals from matrix components can obscure low-level metabolites during data acquisition, making the untargeted fragmentation data acquisition difficult. In this whitepaper<\/a>, Hackbusch et al.<\/em> discuss the benefits of using advanced acquisition strategies to exclude unwanted background information and ultimately simplify the data analysis.<\/p>\n\n\n\n

Additionally, routine metabolite identification work typically relies on collisional dissociation (HCD or CID) to generate diagnostic fragments. However, in some instances the determination of transformation sites can be challenged if only non-specific fragments are generated. Orthogonal fragmentation modes such as ultraviolet photo dissociation (UVPD) can allows for deeper insight. As an example of this benefit, Figure 1 shows the use of UVPD fragments to determine the localization of an acyl-glucoronide bond for a metabolite of diclofenac, which wasn\u2019t possible from HCD fragmentation data.<\/p>\n\n\n\n

Read the complete whitepaper on drug metabolite identification<\/a> and discover our metabolite identification solutions on the Thermo Fisher Scientific website.<\/a><\/p>\n\n\n\n

\"Figure
Figure 1. Comparison of the HCD spectrum of diclofenac (top) with the HCD spectrum for its glucuronate metabolite (middle), showing no additional fragments to permit confirmation of the glucuronide position, and the UVPD spectrum (bottom), which allowed the determination of the acyl-glucuronide bond based on the assigned fragment structure for the unique ion at m\/z 327.<\/em> <\/figcaption><\/figure>\n\n\n\n